CO5170459A1 - Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos - Google Patents

Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos

Info

Publication number
CO5170459A1
CO5170459A1 CO00038318A CO00038318A CO5170459A1 CO 5170459 A1 CO5170459 A1 CO 5170459A1 CO 00038318 A CO00038318 A CO 00038318A CO 00038318 A CO00038318 A CO 00038318A CO 5170459 A1 CO5170459 A1 CO 5170459A1
Authority
CO
Colombia
Prior art keywords
transdermal
strogen
lon
agonists
antagonists
Prior art date
Application number
CO00038318A
Other languages
English (en)
Inventor
Tan Paul Andrew Da
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5170459A1 publication Critical patent/CO5170459A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Un método para tratar a un ser humano en necesidad de terapia con agonista-antagonista de estrógenos, que comprende administrar una cantidad eficaz de dicho agonista-antagonista de estrógenos por medios transdérmicos.
CO00038318A 1999-06-01 2000-05-24 Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos CO5170459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13716499P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
CO5170459A1 true CO5170459A1 (es) 2002-06-27

Family

ID=22476088

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00038318A CO5170459A1 (es) 1999-06-01 2000-05-24 Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos

Country Status (16)

Country Link
EP (1) EP1057480B1 (es)
JP (1) JP2001002588A (es)
KR (1) KR20010029770A (es)
AT (1) ATE269698T1 (es)
AU (1) AU3781000A (es)
CA (1) CA2310272A1 (es)
CO (1) CO5170459A1 (es)
DE (1) DE60011710T2 (es)
DK (1) DK1057480T3 (es)
ES (1) ES2220346T3 (es)
HU (1) HUP0002085A3 (es)
IL (1) IL136376A0 (es)
NZ (1) NZ504868A (es)
PE (1) PE20010207A1 (es)
PT (1) PT1057480E (es)
ZA (1) ZA200002693B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
MXPA02001152A (es) * 2000-06-01 2002-08-20 Watson Pharmaceuticals Inc Suministro transdermico lasofoxifeno.
US20140067048A1 (en) 2012-09-06 2014-03-06 Edwards Lifesciences Corporation Heart Valve Sealing Devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
ZA200002693B (en) 2001-11-30
ATE269698T1 (de) 2004-07-15
CA2310272A1 (en) 2000-12-01
EP1057480A3 (en) 2002-01-09
NZ504868A (en) 2001-09-28
DE60011710D1 (de) 2004-07-29
HU0002085D0 (en) 2000-08-28
DK1057480T3 (da) 2004-11-08
KR20010029770A (ko) 2001-04-16
PE20010207A1 (es) 2001-02-28
HUP0002085A3 (en) 2002-09-30
AU3781000A (en) 2000-12-07
HUP0002085A2 (en) 2001-03-28
IL136376A0 (en) 2001-06-14
PT1057480E (pt) 2004-10-29
JP2001002588A (ja) 2001-01-09
DE60011710T2 (de) 2005-06-30
ES2220346T3 (es) 2004-12-16
EP1057480B1 (en) 2004-06-23
EP1057480A2 (en) 2000-12-06

Similar Documents

Publication Publication Date Title
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
CO4290359A1 (es) Metodo para tratar la alopecia androgenica con inhibidores 5-alfa-reductasa
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
EP1308168A4 (en) NEW MEDICINES FOR CANCER
AR032293A1 (es) Estuche farmaceutico
GB0002336D0 (en) Medicaments
AR021750A1 (es) Aparato para el tratamiento topico localizado de una enfermedad
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
ES2178851T3 (es) Procedimiento para el tratamiento de un articulo que contienen un compuesto organico oxidable.
EA199800866A1 (ru) Способ снятия боли
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
AU2967700A (en) Combination therapy for lymphoproliferative diseases
CO5170459A1 (es) Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
ES1044983Y (es) Aparato de termoestimulacion para tratamientos terapeuticos.
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
ATE245029T1 (de) Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor
ES2141044B1 (es) Terapia con oxibutinina.

Legal Events

Date Code Title Description
FC Application refused